Table 2.
Parameter estimation of the three drugs
| Olanzapine value(RSE%) | Risperidone value(RSE%) | Aripiprazole value 1(RSE%) | Aripiprazole value 2(RSE%) | |
|---|---|---|---|---|
| Pharmacodynamics parameters | ||||
| Emax, % | 80.3(6.7) | 68.2 (11.4) | 44.2(38.9) | 23.9(17.6) |
| ET50, week | 56.7 (16.4) | 29.2 (20.7) | 49.7 (57.9) | 36.8(29.8) |
| Covariate parameters | ||||
| θ1 on Emax | NA | −33.3 (18.2) | NA | NA |
| θ2 on Emax | NA | −0.748 (19.8) | NA | NA |
| θ3 on ET50 | 1.32 (13.6) | NA | NA | NA |
| θ4 on ET50 | NA | 0.524 (62.2) | NA | NA |
| θ5 on ET50 | 2.46 (13.7) | NA | NA | NA |
| Variability parameters | ||||
| η (Emax), % | 22.4(17.9) | 28.0 (28.4) | 58.5 (11.7) | 56.9(13.7) |
| η (ET50), % | 119.6 (10.2) | 110.5 (12.5) | 69.9 (21.3) | − |
| ε, % | 8.062 (12.4) | 8.967 (21.2) | 13.5 (21.9) | 10.7(14.7) |
| Shrinkage | ||||
| Shrinkage _η (Emax), % | 23.7 | 26.8 | 32.5 | 32.7 |
| Shrinkage _η (ET50), % | 34.1 | 40.2 | 53.6 | − |
| Shrinkage _ε, % | 9.7 | 8.9 | 12.6 | 11.5 |
Emax maximal effect of drug, ET50 time to achieve 50% of Emax, θ on Emax or ET50 effect of the parameter θ used to correct the effect on Emax or ET50, η interstudy variability of pharmacodynamic parameter, ε residual error, NA parameter is not estimated, RSE relative standard error. θ1, Episode; θ2, PANSS total score; θ3, Onset frequency; θ4, Course (month); θ5, General psychopathology score. Aripiprazole Value 1, original data set; Aripiprazole Value 2, outliers remove